Transplant (Hematologic) Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
15147A Collection of Research Blood and/or Marrow Samples in Donors Undergoing Bone Marrow, Stem Cell or Lymphocyte Collection.
Select
15953A Protocol for a research database for hematopoietic Stem Cell Transplanation and Marrow Toxic Injuries _ REPLACES 13239B
15961A Protocol for a Research Sample Repository For Allogeneic Hematopioetic Stem Cell Transplanation_ REPLACES 12590A
10-064-B Molecular characterization of hematopoietic malignancies
11-0118 KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Select
12-0064 COG ANBL09P1: A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG/Irinotecan/Vincristine
Select
IRB12-1191 Pilot study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies
Select
IRB12-1924 A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)
12-1856 The University of Chicago Transplant Immunology and Immunogenetics Laboratory Research Registry and Specimen Collection Protocol for Biomedical Research
IRB13-1280 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Select
IRB14-0085 A Phase II, Randomized Trial of Standard of Care, With or Without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
IRB14-0205 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK8228-001)
Select
IRB14-0709 A Phase I Study Of Intensity Modulated Total Marrow Irradiation (IMTMI) In Addition To Fludarabine/Melphelan Conditioning For Allogeneic Transplantation For Advanced Hematologic Malignancies
IRB14-0816 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK8228-001)
Select
IRB14-1106 A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract (GS-US-218-0108)
Select
IRB14-1109 A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract (GS-US-218-1502)
IRB15-0536 Novel Prognostication in Hematopoietic Cell Transplantation (HCT).

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team